愛美客(300896.SZ)：擬以8.86億元取得韓國Huons Bio 25.4%的股權
格隆匯6月24日丨愛美客(300896.SZ)公佈，公司於2021年6月24日召開第二屆董事會第二十三次會議，審議通過了《關於公司使用部分超募資金增資暨收購韓國Huons BioPharma Co., Ltd.部分股權的議案》。
為進一步推進和提升公司國際化戰略佈局能力，通過投資相關領域全球領先企業、引進海外前沿的先進技術和成果來推動公司的發展，鞏固和保持公司的行業領先地位，公司擬使用超募資金約8.86億元人民幣對Huons BioPharma Co., Ltd. (“Huons Bio”或“標的公司”)進行增資並收購Huons Bio部分股權。
此次增資和收購完成後，愛美客合計持有Huons Bio 122萬股股份，持股比例25.4%。
Huons Bio分拆前是Huons Global的肉毒毒素業務部門，其肉毒毒素產品Hutox於2019年4月在韓國取得產品註冊證。2021年4月，Huons Bio從Huons Global分拆設立，目前是Huons Global全資子公司。
Huons Global Co., Ltd.是韓國知名製藥及醫療器械企業，於2006年在韓國證券交易所上市（KOSDAQ:084110）。其主營業務覆蓋大健康多個領域，包括藥物、醫療器械、美容產品、特種醫藥，從護膚品到消毒水，從玻尿酸到新冠病毒檢測試劑盒，知名產品包括德瑪莎水光注射儀、艾莉薇玻尿酸、Hutox肉毒素。
Huons Global旗下成立Huons、Humedix、Huons Medicare、Hubena、Huons Natural、Panace、Huons Nature、Huons USA等多家子公司。其中有2家上市公司：Huons Co Ltd (KOSDAQ:243070)、Humedix Co Ltd (KOSDAQ:200670)。
公司此次使用部分超募資金投資韓國Huons Bio，一方面有利於熟悉、引進海外前沿技術，指導公司應用新技術、新方法，更好、更快的實現研發的階段性成果。另一方面，有利於公司通過對全球不同地區生物製品研發、註冊申報、市場競爭等方面的瞭解與熟悉，制定研發成果在全球進行專利註冊申請，逐步拓展海外市場，提升公司的整體競爭實力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
